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Background. Normalization of plasma ﬁbrinogen levels may be associated with satisfactory
haemostasis and reduced bleeding. The aim of this retrospective study was to assess ﬁbrinogen
recovery parameters after administration of ﬁbrinogen concentrate (Haemocomplettan
w P) to
patients with diffuse bleeding in cardiovascular surgery. Data on transfusion and patient out-
comes were also collected.
Methods. Patient characteristic and clinical data were obtained from patient records. Results
of the thromboelastometry (FIBTEM
w) and of the standard coagulation tests, including plasma
ﬁbrinogen level, measured before surgery, before and after haemostatic therapy, and on the fol-
lowing day, were retrieved from laboratory records.
Results. Thirty-nine patients receiving ﬁbrinogen concentrate for diffuse bleeding requiring hae-
mostatic therapy after cardiopulmonary bypass were identiﬁed. The mean ﬁbrinogen concentrate
dose administered was 6.5 g. The mean ﬁbrinogen level increased from 1.9 to 3.6 g litre
21
(mean increment of 0.28 g litre
21 per gram of concentrate administered); maximum clot ﬁrmness
increased from 10 to 21 mm. The mean ﬁbrinogen increase was 2.29 (SD 0.7) mg dl
21 per mg
kg
21 bodyweight of concentrate administered. Thirty-ﬁve patients received no transfusion of
fresh-frozen plasma (FFP) or platelet concentrate after receiving ﬁbrinogen concentrate; the
remaining four patients received platelet concentrate intraoperatively. Eleven patients received
platelets, FFP , or both during the ﬁrst postoperative day. No venous thromboses, arterial ischaemic
events, or deaths were registered during hospitalization.
Conclusions. In this retrospective study, ﬁbrinogen concentrate was effective in increasing
plasma ﬁbrinogen level, and contributed to the correction of bleeding aftercardiovascular surgery.
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Most coagulation defects resulting from massive haemor-
rhage during surgery are caused by dilutional coagulopa-
thy (loss, consumption, dilution, or both of coagulation
factors, and reduction of clot stability by artiﬁcial col-
loids). Fibrinogen is the ﬁrst coagulation factor to become
critically reduced during major surgical blood loss.
1 In a
pig model of dilutional coagulopathy, the increase in ﬁbri-
nogen synthesis cannot compensate for the increased
breakdown even if blood loss is only moderate.
2 The
observation that patients with higher ﬁbrinogen levels
experience fewer bleeding complications than those with
low levels further highlights the importance of ﬁbrinogen
in the maintenance of haemostasis.
3–5 In addition, cardiac
surgery is associated with particular complications. For
example, interactions with the extracorporeal surfaces of
the heart–lung machine during cardiopulmonary bypass
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6
Fresh-frozen plasma (FFP) contains all plasma coagu-
lation factors, but the concentration of ﬁbrinogen is not
sufﬁcient for the treatment of severe deﬁciency.
78
Cryoprecipitate is a more concentrated source of ﬁbrino-
gen available in the USA and UK. However, its use is
poorly standardized,
9 and safety concerns led to its with-
drawal from most European countries. Fibrinogen concen-
trate was recently licensed in the USA and is well
established in Central Europe for the treatment of congeni-
tal ﬁbrinogen deﬁciency. In Central Europe, it is also
increasingly used for management of acquired ﬁbrinogen
deﬁciency.
81 0–15
Administration of ﬁbrinogen concentrate has been shown
to improve clot ﬁrmness and reduce blood loss using in
vitro and pig models of dilutional coagulopathy.
16 17
Furthermore, a high dose of ﬁbrinogen concentrate was
more effective than transfusion of platelet concentrates in
decreasing the rate of blood loss and prolonging survival
time in a pig model,
18 indicating that raising ﬁbrinogen
levels might compensate for low platelet counts. This
observation was conﬁrmed in a retrospective analysis of
clot quality in 904 thrombocytopenic patients.
19 Clinical
studies have provided evidence for the efﬁcacy and toler-
ability of ﬁbrinogen concentrate in congenital ﬁbrinogen
deﬁciency,
20 21 and data on its use in patients with
acquired deﬁciency in a variety of surgical settings are
beginning to emerge.
81 01 2 –15 22–24 A recently published
randomized placebo-controlled trial showed that adminis-
tration of ﬁbrinogen concentrate in patients undergoing
radical cystectomy reduced the requirement for postopera-
tive transfusion.
11
This retrospective study assessed recovery parameters of
ﬁbrinogen after administration of ﬁbrinogen concentrate to
patients with diffuse bleeding after weaning from CPB in
cardiac surgery. Data on transfusion of allogeneic blood
products, local reactions, major thromboembolic compli-
cations, 24 h survival, and survival until discharge from
hospital were also collected.
Methods
Study design and patient population
This was an open-label, uncontrolled, retrospective study
conducted in the cardiothoracic surgery department of
Hannover Medical School between December 2006 and
December 2008. After research ethics board approval, data
were obtained from pharmacy-dispensing records, anaes-
thesia records, and standard coagulation laboratory
records. The analysis included all patients who received
ﬁbrinogen concentrate for active bleeding who also had
their plasma ﬁbrinogen levels documented before and after
ﬁbrinogen concentrate administration. Data from patients
with concomitant administration of haemostatic medi-
cation containing ﬁbrinogen (FFP), non-elective or emer-
gency intervention, age ,18 yr, and terminal illness were
excluded from the analysis.
Evaluation
The following information was collected: age, gender,
weight, BMI, surgery details, and any adverse events docu-
mented in the clinical records. In addition, standard
laboratory test results [ﬁbrinogen, prothrombin time (PT),
activated partial thromboplastin time (aPTT), platelet count,
haemoglobin, and haematocrit] were collected from the
laboratory records. The time points included were: before
surgery (baseline), before haemostatic therapy (at the end of
CPB), before the end of surgery, and the following day.
Fibrinogen analysis
Thromboelastometric measurement of the ﬁbrin-based clot
was performed using the FIBTEM
w test as described pre-
viously.
25 The maximum clot ﬁrmness (MCF) parameter
reﬂects the total ﬁrmness of the clot formed in the pres-
ence of platelet inhibition with cytochalasin D. Plasma
ﬁbrinogen levels were determined using the Clauss
method (STA-R device and reagents, Diagnostica Stago,
Asnieres, France). Median increase (response) in mg dl
21
per mg kg
21 bodyweight of ﬁbrinogen was calculated, and
also the median increment (g litre
21) per 1 g ﬁbrinogen
concentrate administered. In vivo recovery was calculated
as the actual increase in ﬁbrinogen level divided by the
expected increase in ﬁbrinogen (mg dl
21100), where the
expected increase in ﬁbrinogen was the dose of ﬁbrinogen
(mg) divided by the plasma volume (ml). The plasma
volume was calculated as 70bodyweight (kg)(100–
haematocrit)100
21.
Clinical management
Anaesthesia was induced with etomidate 0.3 mg kg
21, fen-
tanyl 8 mgk g
21, and cisatracurium 0.2 mg kg
21. During
the induction of anaesthesia, patients received lactated
Ringer’s solution and gelatin polysuccinate (Gelafundin
w
0.026; Serumwerk, Bernburg, Germany). For maintenance
of anaesthesia, sevoﬂurane was titrated to an end-tidal con-
centration of 1–2% until institution of CPB. For the dur-
ation of CPB, propofol was infused at 50–80 mgk g
21
min
21 and additional 4 mgk g
21 boluses of fentanyl were
administered every 30 min for the duration of CPB. CPB
was established after cannulation and administration of
400 IU kg
21 of heparin (Heparin-Natrium-2500-
ratiopharm
w, Merckle GmbH, Blauberen, Germany); mod-
erate hypothermia (348C) was used. Aprotinin was used in
all but three patients, who received tranexamic acid.
After weaning from bypass, administration of protamine
and completion of surgical haemostasis, virally inactivated,
pasteurized ﬁbrinogen concentrate (Haemocomplettan
w
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556P, CSL Behring, Marburg, Germany) was administered as a
ﬁrst-line coagulation therapy to patients with diffuse bleed-
ing. The dosing of ﬁbrinogen concentrate was guided by
FIBTEM thromboelastometry.
13 14 The ﬁbrinogen dose (g)
administered to increase FIBTEM MCF was calculated
using the formula (target FIBTEM MCF–actual FIBTEM
MCF)bodyweight/140, which corresponds to 0.5 g of
ﬁbrinogen concentrate needed to raise MCF by 1 mm in a
70 kg patient. Fibrinogen concentrate was administered
regardless of platelet count; platelet concentrate was admi-
nistered as a second-line haemostatic therapy. Red blood
cells (RBCs) were transfused to maintain haematocrit
values between 23% and 25% on CPB and above 28% after
CPB after blood from the extracorporeal circulation system
was re-infused. Transfusion in the intensive care unit (ICU)
was administered when the drainage volume was higher
than 400 ml h
21 and consisted of platelet concentrate for
platelet count ,10010
3 ml
21 and FFP for prolongation of
PT .1.5 times normal.
Statistical analysis
Normality of data distribution was tested using the
Kolmogorov–Smirnov test. Results are expressed as mean
and standard deviation (SD), median (25th percentile, 75th
percentile), or number and percentage. Differences between
time points were analysed using the paired Student’s t-test
with Bonferroni’s correction for repeated measurements.
Statistical signiﬁcance was deﬁned as P,0.05.
Results
Thirty-nine patients treated for active bleeding with ﬁbri-
nogen concentrate were identiﬁed. Of these, 34 (87%)
were male; mean age was 58 (range: 25–78) yr; mean
weight was 85 (SD 17.3) kg; and mean BMI was 27.5 (4.6)
kg m
22. Surgical procedures are summarized in Table 1;
most patients underwent aortocoronary bypass (ACB),
aortic valve and ascending aortic aneurysm surgery, or
thoracoabdominal aortic aneurysm surgery. Aspirin intake
within 5 days of surgery was reported in six patients
undergoing ACB (60%) and in four patients undergoing
repeat ACB (80%). One patient undergoing repeat ACB
was reported to have taken clopidogrel within 5 days of
surgery.
At the end of CPB, PT and aPTT were signiﬁcantly pro-
longed, and platelet count, haemoglobin, and haematocrit
were signiﬁcantly reduced compared with baseline values
(Table 2). After the administration of ﬁbrinogen concen-
trate, there were no signiﬁcant changes in platelet count,
haemoglobin, or haematocrit. PT was slightly shortened
(from 20.8 to 20.1 s), whereas aPTT was prolonged (from
26.6 to 41.5 s). Before administration of ﬁbrinogen con-
centrate, mean Clauss ﬁbrinogen was 1.9 (0.6) g litre
21
(Table 2, Fig. 1). The mean dose of ﬁbrinogen concentrate
administered was 6.5 (1.6) g or 78 (20) mg kg
21. The ﬁrst
post-therapy sample was obtained before the end of
surgery, ,1 h after ﬁbrinogen concentrate administration.
At this time, mean Clauss ﬁbrinogen level was 3.6 (0.7) g,
which was signiﬁcantly higher (P,0.001) than at the end
of CPB (Table 2). Of importance, this value did not differ
signiﬁcantly from the baseline value of 3.3 (1.0) g litre
21.
The mean Clauss ﬁbrinogen level increased in all patients
after ﬁbrinogen concentrate administration [mean absolute
increase 1.7 (0.5) g litre
21; Table 3]. Fibrinogen recovery
is detailed in Table 3. The calculated in vivo recovery of
ﬁbrinogen was .100%. FIBTEM MCF increased from
10.1 (3.7) to 20.7 (3.9) mm (Table 2), and the mean ﬁbri-
nogen dose required to increase FIBTEM MCF by 1 mm
was 7.6 (2) mg kg
21 bodyweight (Table 3).
Intraoperative allogeneic blood products included RBC
(administered to two patients) and platelet concentrate
(administered to four patients in whom bleeding had not
ceased after ﬁbrinogen concentrate therapy). No FFP was
transfused intraoperatively. Thirty-ﬁve patients (90%)
received no intraoperative transfusions after the adminis-
tration of ﬁbrinogen concentrate.
Twenty-eight patients (72%) received no postoperative
transfusions. During the ﬁrst postoperative day, one patient
received only RBC transfusion, whereas 11 patients
received haemostatic therapy: ﬁve patients received plate-
let concentrate and FFP, and six patients received only
FFP. Of these 11 patients, eight received haemostatic
therapy according to the intensivist’s clinical judgement
and ICU standards. In the remaining three patients,
re-thoracotomy was performed because of suspected
bleeding. In all three of these cases, a surgical source of
bleeding was identiﬁed, and FFP and platelet concentrates
were administered. No venous thromboses, arterial ischae-
mic events, or deaths were identiﬁed up to the time when
patients were discharged from hospital.
Discussion
In the present retrospective analysis, administration of a
mean dose of 6.5 g of ﬁbrinogen concentrate in
Table 1 Type and details of surgery for the 39 patients included in the study.
AV–AA, aortic valve and ascending aortic aneurysm; ICU, intensive care
unit; TAAA, thoracoabdominal aortic aneurysm
Type of surgery [n (%)]
Aortocoronary bypass 10 (25.5)
Re-aortocoronary bypass 5 (13)
TAAA 10 (25.5)
Re-TAAA 1 (3)
AV–AA 13 (33)
Surgery details [mean (SD)o rn (%)]
CPB duration (min) 109.3 (45.1)
Lowest temperature on CPB (8C) 33.4 (2.7)
ICU time to extubation (h) 34.2 (104.1)
ICU time (h) 50.4 (102.8)
Re-exploration for bleeding 3 (8)
24 h postoperative drainage volume (ml) 623.6 (400)
Postoperative hospital stay (days) 11.7 (6.3)
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557cardiovascular surgery patients with diffuse bleeding after
weaning from CPB was followed by an 89% increase in the
ﬁbrinogen plasma level and in vivo recovery of 114%. Our
results showed that the administration of a mean dose of
ﬁbrinogen concentrate of 6.5 g increased plasma ﬁbrinogen
levels by a mean of 1.7 g litre
21, with an increment of 2.3
gl i t r e
21 per substituted mg kg
21 bodyweight. This ﬁnding
is not in agreement with other studies investigating the
administration of ﬁbrinogen concentrate for haemostatic
therapy in acquired ﬁbrinogen deﬁciency. In the observa-
tional study performed by Danes and colleagues
8 investi-
gating 69 patients suffering from various forms of acquired
severe hypoﬁbrinogenaemia, a mean absolute increase of
1.09 g litre
21 of plasma ﬁbrinogen was measured 24 h after
a median dose of 4 g of ﬁbrinogen concentrate (Table 4). In
another retrospective study of 43 patients, Fenger-Eriksen
and colleagues
22 showed an increase in ﬁbrinogen of 1.01 g
litre
21 with only half the dose (median 2 g) of ﬁbrinogen
concentrate (Table 4). The differences in the increase of
ﬁbrinogen plasma concentration may reﬂect differences
between the study populations such as underlying clinical
conditions (e.g. sepsis, haematological malignancy, and
liver insufﬁciency),
8 mean age (52 and 49.5 yr in the
studies by Danes and colleagues
8 and Fenger-Eriksen and
colleagues,
22 respectively), and the proportion of paediatric
patients (2.9% and 9.3% in the studies by Danes and col-
leagues
8 and of Fenger-Eriksen and colleagues,
22 respect-
ively). The patients included in our study were all aged
.18 yr [mean age 58 (SD 11) yr], and cardiovascular
surgery was the only clinical condition. Furthermore, our
retrospective analysis excluded patients receiving additional
medication containing ﬁbrinogen (i.e. FFP) between the
pre- and post-therapy analysis of ﬁbrinogen concentration.
Administration of haemostatic products containing ﬁbrino-
gen in addition to ﬁbrinogen concentrate between the pre-
and post-therapy time could have inﬂuenced the ﬁbrinogen
recovery parameters reported previously. It is difﬁcult to
estimate whether recovery values would have been higher
or lower in the previous reports in the absence of FFP
administration. The concentration of ﬁbrinogen in FFP
varies between units but is generally lower than the plasma
concentrations reached in our patients. Above a target level
of 2.25 g litre
21, which is the mean concentration of ﬁbri-
nogen in plasma thawed after more than 24 h of storage,
26
FFP is likely to act as a diluent and decreases the plasma
ﬁbrinogen concentration.
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Fig 1 Box-and-whisker plots of plasma ﬁbrinogen levels measured using
the Clauss method at baseline, end of CPB, after administration of
ﬁbrinogen concentrate, and during the ﬁrst postoperative day. The boxes
represent the lower (25th) and upper (75th) quartiles, the horizontal line
represents the mean, the whiskers extend to 95% conﬁdence intervals for
the mean, and the circle represents an outlier. Grey shading indicates the
normal range of plasma ﬁbrinogen levels.
Table 2 Standard laboratory data at different time points. Values are presented as the mean (SD). PT, prothrombin time; aPTT, activated partial thromboplastin
time; CPB, cardiopulmonary bypass; FIBTEM, thromboelastometric test investigating ﬁbrin-based clot; MCF, maximum clot ﬁrmness. P-values:
1end of CPB vs
baseline,
2after ﬁbrinogen vs end of CPB,
3ﬁrst postoperative day vs after ﬁbrinogen; *P,0.05; **P,0.001
Parameter Mean (SD)( n539)
Baseline End of CPB (before ﬁbrinogen
concentrate therapy)
1
After ﬁbrinogen concentrate
therapy, before the end of
surgery
2
First
postoperative day
3
PT (s; normal range, 11–13.5) 14.1 (1.2) 20.8 (3.1)** 20.2 (3.9)* 16.6 (1.7)**
aPTT (s; normal range, 26–35) 30.3 (2.8) 36.6 (11.5)** 42.0 (11.4)* 37.3 (9.8)*
Platelet count (10
3 ml
21, normal range, 150–450) 192.6 (52.2) 101.5 (49.5)** 104.0 (38.7) 121.5 (39.6)*
Haemoglobin (g dl
21, normal range, 13.5–17.5) 13.1 (1.4) 9.9 (1.1)** 9.7 (1.2) 10.4 (1.1)*
Haematocrit (%, normal range, 41.5–50.4) 37.8 (3.9) 28.5 (3.1)** 27.7 (3.4) 30.5 (3.4)*
FIBTEM MCF (mm, normal range 9–25) 15.5 (4.9) 10.1 (3.7)** 20.7 (3.9)** 22.3 (2.3)*
Fibrinogen (g litre
21, normal range, 2.0–4.5) 3.3 (1.0) 1.9 (0.6)** 3.6 (0.7)** 4.5 (0.7)**
Table 3 Recovery parameters of the administered ﬁbrinogen concentrate.
FIBTEM, thromboelastometric test investigating ﬁbrin-based clot; MCF,
maximum clot ﬁrmness; SD, standard deviation
Parameter Mean (SD)
(n539)
Absolute increase in ﬁbrinogen (g litre
21) 1.7 (0.5)
Fibrinogen increment (g litre
21 per 1 g ﬁbrinogen
administered)
0.28 (0.1)
Increase (response) in mg dl
21 per substituted mg kg
21
bodyweight
2.3 (0.7)
In vivo recovery (%) 114 (32)
Mean dose of ﬁbrinogen to increase FIBTEM MCF by
1 mm (mg kg
21 bodyweight)
7.6 (2.0)
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and colleagues
8 and 114% in the present study) can be
explained by the slightly hypovolaemic conditions that
commonly occur after surgery. Prolonged bleeding in the
ICU or a postoperative increase in ﬁbrinogen as part of the
acute phase reaction can also inﬂuence plasma ﬁbrinogen
over a time frame of hours.
81 52 2Earlier measurement
(e.g. within 1 h of administration, as in the present study)
might overcome this limitation. Values of recovery above
100% also raise the question whether the amount of ﬁbri-
nogen present in the vials was higher than 1 g, the amount
indicated on the label. Batches of Haemocomplettan P
vary slightly in ﬁbrinogen content, since this concentrate
is a biological product fractionated from FFP (cryoprecipi-
tate). The packet insert indicates a range of 900–1300 mg
per 1 g vial. However, this does not represent the actual
variation in the amount of ﬁbrinogen; instead, this is the
theoretical variation allowed. We performed a review of
the certiﬁcates of analysis of ﬁbrinogen concentrate
batches and found a high degree of consistency in ﬁbrino-
gen content: vials were overﬁlled by a mean 8.75% at the
beginning of the shelf-life to compensate for several
factors that lead to loss of ﬁbrinogen during adminis-
tration: ﬁbrinogen solution remaining in the vial, transfer
from the glass vial into syringes, ﬂuid remaining in the
perfusion line, etc. In the present report, recovery was cal-
culated according to the label (1 g per vial) and not
according to the actual amount of ﬁbrinogen administered,
because in clinical practice, the concentrate is generally
dosed according to the label.
In our clinic, ﬁbrinogen concentrate is administered con-
siderably more rapidly (e.g. 6 g in 1–2 min) for severe
bleeding occurring intraoperatively than in a non-acute
setting (e.g. congenital deﬁciency) in order to obtain a
prompt haemostatic response. This infusion rate is higher
than the rate recommended in the package insert (5 ml
min
21, representing a 60 min infusion time for 6 g).
However, it is unclear how different infusion rates inﬂu-
ence the increase in ﬁbrinogen concentration measured
after 1 h; further investigations are warranted for the peri-
operative setting where rapid correction of severe bleeding
is required.
The mean dose of 6.5 g ﬁbrinogen concentrate adminis-
tered here was higher than the doses administered in
acquired hypoﬁbrinogenaemia in other studies, including
cardiac surgery patients.
81 01 52 3In the guidelines recently
published by the German Medical Association, it is
suggested that adults will generally require a single dose
of 3–6 g of ﬁbrinogen concentrate.
27 Importantly, the
mean level of ﬁbrinogen after administration of ﬁbrinogen
concentrate was comparable with baseline levels, which
correspond to levels reported for healthy subjects of
similar age.
28 The high-normal target level of ﬁbrinogen
was chosen based on observations regarding the protective
role of high ﬁbrinogen concentration against bleeding in
cardiac and non-cardiac settings.
3–5 On the basis of the
results of previous in vitro investigations,
18 19 high ﬁbrino-
gen concentration might have compensated for decreased
platelet counts with regard to clot ﬁrmness.
The administration of ﬁbrinogen concentrate and the cal-
culation of recovery parameters is generally based on the
plasma ﬁbrinogen level measured using the Clauss method
(turbidimetric read-out). In our department, however, admin-
istration of ﬁbrinogen concentrate is most often guided by
the thromboelastometric FIBTEM test because of its rapidity
and its reﬂection of the mechanical strength of the clot.
There are reports on the use of FIBTEM to guide haemo-
static therapy in several settings, including orthopaedic
surgery, trauma, and cardiovascular surgery.
10 13 14 29 MCF
target levels above 7 mm have been considered for orthopae-
dic surgery,
10 whereas in cardiovascular surgery, a consider-
ably higher target has been discussed (22 mm).
13 14 There is
currently no evidence for these target levels, and random-
ized controlled trials investigating this therapeutic approach
appear desirable. Nevertheless, FIBTEM appears to be a
valuable means of guiding ﬁbrinogen concentrate therapy in
the perioperative setting. Although a correlation between
plasma ﬁbrinogen concentration and FIBTEM MCF has
been reported,
30 neither FIBTEM nor the Clauss method
measure ﬁbrinogen concentration directly. The Clauss
method measures the time to ﬁbrin formation and compares
it with a calibration curve.
31 The result is therefore a clotting
time, from which the concentration of ﬁbrinogen can be
derived. When obtained using a photo-optical technique, as
in the present report, the result may be affected by many
functional ﬁbrinogen-independent factors, such as ﬁbrinogen
degradation products that have an anticoagulant effect, ﬁbrin
degradation products, haemodilution with hydroxyethyl
Table 4 Previously published data on plasma ﬁbrinogen recovery in patients with acquired hypoﬁbrinogenaemia. N/R, not reported
Study
Danes and
colleagues
8
Fenger-Eriksen and
colleagues
22
Weinkove and
Rangarajan
15
Number of patients treated 69 43 30
Fibrinogen dose (g) 4 2 4
Absolute dose range (g) 0.5–8 1–5 2–14
Average increase of plasma ﬁbrinogen (g litre
21) 1.09 1.01 1.19
Median (range) increment per 1 g ﬁbrinogen concentrate (g litre
21) 0.28 (0–3.7) N/R 0.25 (0.07–0.84)
In vivo recovery (%) 109.1 N/R N/R
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32 or factors that inﬂuence turbidity (e.g. lipid con-
centration in the plasma sample, bile pigment, and free hae-
moglobin). Fibrinogen values obtained when using the
Clauss method are therefore prone to inaccuracy. FIBTEM,
a test for assessing the elasticity of the ﬁbrin clot under
platelet inhibition by cytochalasin D, is more a measurement
of ﬁbrin quality rather than a ﬁbrinogen measurement.
FIBTEM MCF is mainly dependent on ﬁbrinogen concen-
tration, but as with the Clauss assay, it is subject to the inﬂu-
ence of ﬁbrinogen-independent factors. FXIII appears to be
one of these factors.
33 The present data show that after
therapy, the mean ﬁbrinogen increased to 189% of the pre-
therapy value, whereas the mean FIBTEM MCF increased
to 200%. The apparently higher increase in FIBTEM MCF
may have been related to small amounts of FXIII in the
ﬁbrinogen concentrate (i.e. 50 IU FXIII per 1 g ﬁbrinogen
concentrate). As FXIII has been shown to help maintain clot
ﬁrmness in haemodilution,
34 it appears necessary to investi-
gate further its haemostatic role in the present setting.
The records of the patients included in the study showed
no venous thromboses or arterial ischaemic events.
Regarding the safety of ﬁbrinogen concentrate adminis-
tration, a 22 yr pharmacovigilance programme and a sys-
tematic review of clinical studies indicated that the
thrombogenic potential of Haemocomplettan
w Pi sl o w .
35
In fact, given its role as a substrate for formation of the
ﬁbrin net, ﬁbrinogen may play an important antithrombotic
role. Fibrin, known as antithrombin I, acts by sequestering
thrombin in the incipient clot, reducing the activity of the
bound thrombin, and localizing the subsequent processes
of clot formation.
36 Sufﬁcient formation of the ﬁbrin net
may be beneﬁcial at the end of CPB, when antithrombin
levels are decreased,
37 and reversal of heparinization is
induced with protamine.
Nevertheless, caution is required when administering
ﬁbrinogen concentrate for the treatment of bleeding after
ACB, because there are few data on the inﬂuence of this
therapy on graft patency or on its safety in this setting. In
a prospective study of 10 ACB patients, prophylactic
administration of ﬁbrinogen concentrate increased baseline
ﬁbrinogen concentration of 2.9 by 0.7 g litre
21, and no
clinically relevant postoperative thrombotic events were
observed.
24 High preoperative ﬁbrinogen values (.3.5 g
litre
21) in ACB have been shown to predict postoperative
mortality of all cause, but not the mortality from cardiac
cause or the need for myocardial vascularization,
38 sup-
porting the hypothesis that ﬁbrinogen was a marker of
inﬂammation, rather than a cause of thrombosis in these
patients. On the other hand, decreased preoperative ﬁbrino-
gen values have been shown to correlate with bleeding
after ACB,
5 possibly because they lead to low ﬁbrinogen
values when weaning from CPB. In contrast to the prophy-
lactic approach, some clinicians favour administration of
ﬁbrinogen concentrate only for therapy of overt bleeding,
as in the present study. It remains to be established
whether administering ﬁbrinogen concentrate as
prophylaxis or for correction of bleeding in a dosage
adjusted according to bodyweight, actual ﬁbrinogen level
or ﬁbrin-based clot ﬁrmness is a more viable strategy
when using ﬁbrinogen concentrate as haemostatic therapy
for severe bleeding post-CPB.
One limitation of the current study is variation in the
type of cardiac surgery. Also, bleeding and necessity for
transfusion were judged clinically, which could introduce
bias. A further limitation of the study is that the ﬁbrinogen
recovery parameters were calculated from values obtained
towards the end of surgery, and not immediately after
administration of ﬁbrinogen concentrate. Infusion of col-
loids, crystalloids, or blood from cell-saver could have inﬂu-
enced the recovery parameters. However, with bleeding
already corrected by the haemostatic therapy, the patients
were in a stable condition at this time, and the impact of
plasma loss or replacement would have been limited.
Furthermore, it is important to keep in mind that the com-
parability of pharmacokinetic data presented in different
reports is limited if different methods of ﬁbrinogen
measurement are used.
39 An u m b e ro fd i f f e r e n ta s s a y s
based on the Clauss method are commercially available,
and they vary in thrombin strength, buffer composition,
inclusion of inhibitors of heparin and ﬁbrinogen degradation
products, calibration method, and dilution range. Even
when calibrated correctly, Clauss assays can differ up to
50%.
32 40 Recently, Fenger-Eriksen and colleagues
41
showed that the results of Clauss measurement differ sig-
niﬁcantly in the presence of colloid plasma expander when
using different automated coagulation analysers. Variability
can also be introduced by different commercially available
calibrators,
42 or by heterogeneity of ﬁbrinogen (high mol-
ecular weight fraction/low molecular weight fraction) in
different patient groups compared with the calibration
material.
43 44 Each of these factors alone might not be clini-
cally relevant in the perioperative setting, but taken together
they could invalidate comparisons between studies.
In conclusion, this retrospective analysis showed that
ﬁbrinogen concentrate administered for haemostatic
therapy in cardiovascular surgery was effective in increas-
ing the plasma ﬁbrinogen level and contributed to the cor-
rection of bleeding. Prospective investigation of this
therapeutic approach appears warranted.
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